Skip to main content

CryptoBreaking News

Bloomberg

Extended Oil Shock Spells Higher, Sticky Inflation

The amount of inflation priced into 10-year Treasury yields is a little hard to square with what the market is saying about price rises in the near term. Either inflation is going to be high for a long time, and this is something that has changed in the past week or two, or 10-year yields have gone a little too far. Yelena Shulyatyeva, Senior US Economist at The Conference Board, discusses inflation expectations and what happens if oil prices rise higher, for longer.

Read more: Extended Oil Shock Spells Higher, Sticky Inflation
Bloomberg

5% is New 4% in Era of Higher Yields, Says Guneet Dhingra

A new era of elevated borrowing costs is potentially underway as war-driven inflation angst intensifies in the US bond market, sending 30-year yields toward a two-decade high above 5%. Guneet Dhingra, Head of US Rates Strategy at BNP Paribas, discusses the recent yield surge and why 5% may become the new 4%.

Read more: 5% is New 4% in Era of Higher Yields, Says Guneet Dhingra
Bloomberg

Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers

On this episode of Stock Movers with Alexis Christoforous: - NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas. - Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs. - Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker's phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the "disappointing" trial update.

Read more: Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers
Bloomberg

NextEra to Buy Dominion to Form Power Giant

Joe Kaiser, the CEO of Switchyard Partners, joined Bloomberg Open Interest to explain why the massive NextEra, Dominion merger is really about powering the AI boom. He breaks down how hyperscale data centers are reshaping the US energy grid, why regulators will likely approve the deal, and why renewable energy plus natural gas will define the next era of AI infrastructure.

Read more: NextEra to Buy Dominion to Form Power Giant